Can-Fite BioPharma Reports Namodenoson Pancreatic Cancer Findings
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
Phase 2b
Advertisement
Eupraxia Reports Durable EoE Symptom Improvements With EP-104GI
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
CalciMedica Advances Auxora and CM5480 in Pulmonary Hypertension
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
Veru Advances PLATEAU Trial with Full Enrollment
Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...
Veru Completes Enrollment in Phase 2b PLATEAU Obesity Trial
MIAMI, Fla., July 27, 2026 Veru Inc. announced the successful completion of patient enrollment in its Phase 2b PLATEAU...
Advertisements
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
NextCure and Avere Strengthen Oral IL-23 Development
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
CervoMed Reports Positive Clinical, Biomarker and MRI Data for Neflamapimod at AAIC 2026
BOSTON, July 14, 2026 CervoMed presented new clinical, plasma biomarker, pharmacokinetic, and imaging analyses at the Alzheimer’s Association International...
Vaccinex Showcases Pepinemab Biomarker Results
ROCHESTER, N.Y., July 8, 2026 Vaccinex announced that it will present new biomarker findings from its Phase 1b/2 SIGNAL-AD...
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
Advertisement
